Pfizer

Stories 1 - 20 |  Next >>

Wait for the Next Booster, Officials Tell Adults Under 50

Moderna, Pfizer assure government updated omicron version will be ready for fall

(Newser) - Federal health officials have decided against approving a second booster shot of the coronavirus vaccine this summer for adults under 50, because a retooled version is so close to being ready. Pfizer and Moderna have assured the government their new boosters will be rolled out no later than September, the...

FDA Advisers Endorse Vaccines Starting at 6 Months

Age group is the only one without access to COVID vaccines in US

(Newser) - COVID-19 shots for US infants, toddlers, and preschoolers moved a step closer to reality on Wednesday. The Food and Drug Administration's vaccine advisers gave a thumbs-up to vaccines from Moderna and Pfizer for the littlest kids. The outside experts voted unanimously that the benefits of the shots outweigh any...

FDA Posts Analysis of Pfizer Shots for Kids Under 5

Says the kid-sized dose appears to be safe and effective

(Newser) - Update: The FDA on Sunday posted its analysis of Pfizer’s COVID-19 vaccine for children under age 5, announcing that the kid-sized doses do appear to be safe and effective. The agency posted a similar analysis of Moderna's vaccine for the youngest age group last week. Next up: Wednesday'...

Pfizer Offers Update on Shots for Kids Under 5

Preliminary data suggest 3 shots offer strong protection for the youngest patients

(Newser) - Three doses of Pfizer's COVID-19 vaccine offer strong protection for children younger than 5, the company announced Monday. Pfizer plans to give the data to US regulators later this week in a step toward letting the littlest kids get the shots. The news comes after months of anxious waiting...

CDC Panel Backs Booster for Ages 5-11
CDC: Children
5-11 Should
Get a Booster
updated

CDC: Children 5-11 Should Get a Booster

Rise in coronavirus cases prompts advisers' decision

(Newser) - Update: This file has been updated throughout with the CDC's decision. Children ages 5 to 11 should get a booster dose of Pfizer's COVID-19 vaccine, the Centers for Disease Control announced Thursday. An advisory panel had made the recommendation earlier in the day. The move opens a third...

Pfizer Wants FDA to OK Boosters for 5- to 11-Year-Olds

3rd dose among this set appears to offer significant antibody boost, even against omicron

(Newser) - Pfizer said Thursday it wants to expand its COVID-19 booster shots to healthy elementary-age kids. US health authorities already urge everyone 12 and older to get one booster dose for the best protection against the newest variants—and recently gave the option of a second booster to those 50 and...

Yes, Pfizer Recipients Will Need 4th Dose: CEO
Pfizer CEO
Says 4th Dose
'Is Necessary'
UPDATED

Pfizer CEO Says 4th Dose 'Is Necessary'

But he's hoping company will soon have a shot that works against all variants

(Newser) - Update: Pfizer, along with its partner BioNTech, on Tuesday asked US regulators to authorize an additional COVID vaccine booster for seniors. The pharmaceutical company says data from Israel as well as an ongoing study of healthcare workers suggest those 65 and older would benefit from a fourth dose, the AP...

Pfizer Seeks Approval for Vaccine for Kids Under 5

Regulator urged company to apply earlier than planned

(Newser) - Pfizer on Tuesday asked the US to authorize extra-low doses of its COVID-19 vaccine for children under 5, potentially opening the way for the very youngest Americans to start receiving shots as early as March. In an extraordinary move, the Food and Drug Administration had urged Pfizer and its partner...

Omicron-Specific Booster Trials Are Now Underway

Moderna cites 'long-term threat demonstrated by omicron's immune escape'

(Newser) - The first participant has received a shot in Moderna's Phase 2 clinical trial of an omicron-specific vaccine booster. Moderna, which made the announcement Wednesday, expects to enroll 600 adults in the US study, including some who have already received a booster shot, per Reuters . "We are reassured by...

'Lot of Infections' From Omicron After 4th Dose: Trial

In preliminary study from Israel, the first of its kind, antibodies rise after 2nd booster, infections persist

(Newser) - Preliminary results are in on a clinical trial testing the efficacy of a fourth COVID shot, the world's first, and when it comes to omicron, that booster isn't doing the job researchers had hoped for. The Times of Israel reports that, in a study that began last month...

Slumping Health, Tech Stocks Drag S&P 500 Down
Pfizer Stock Drops
for 2nd Day in a Row
MARKETS

Pfizer Stock Drops for 2nd Day in a Row

Health, tech stocks dragged down S&P 500 but Dow hit a new record high

(Newser) - Slumping technology stocks left the S&P 500 slightly lower on Wall Street Tuesday, even as the Dow Jones Industrial Average of 30 blue-chip companies marked another record high. Microsoft, Apple, and major chipmakers like Nvidia sank while banks and other sectors rose. Bond yields continued to climb. The yield...

FDA: Fine to Get Booster After Just 5 Months

It also now recommends boosters for kids 12 to 15

(Newser) - The US is expanding COVID-19 boosters as it confronts the omicron surge, with the FDA allowing extra Pfizer shots for children as young as 12. Boosters already are recommended for everyone 16 and older, and federal regulators on Monday decided they're also warranted for 12- to 15-year-olds once enough...

Pfizer Asks US Officials to OK COVID Pill
FDA Approves First COVID Pill
UPDATED

FDA Approves First COVID Pill

Regulators call Pfizer's Paxlovid pill a 'major step forward' in fight against pandemic

(Newser) - Update: The FDA has approved the first pill to treat COVID-19 at home—and not a moment too soon. Pfizer's Paxlovid antiviral pill was initially seen as an extra drug in the anti-COVID arsenal, but with cases surging and antibody treatments not working against the omicron variant, the pills...

Good News on Moderna Booster
Good
News on
Moderna
Booster

Good News on Moderna Booster

Early lab results suggests third shot provides significant protection against omicron

(Newser) - Lab results from Moderna add to health officials' chorus on omicron: Get a booster. The company said Monday that preliminary results suggests a third shot of its vaccine provides significant protection against the new variant. The usual half-dose booster raised antibody levels 37-fold, while a full-dose booster—typically given to...

CDC Panel Backs Other Vaccines Over J&J's
CDC:
Get Pfizer or
Moderna,
Not J&J
UPDATED

CDC: Get Pfizer or Moderna, Not J&J

CDC makes official new recommendation

(Newser) - Update: The CDC is now officially taking the stance that that "mRNA vaccines are preferred over [Johnson & Johnson's] Janssen COVID-19 vaccine for the prevention of COVID-19 for those 18 years of age and over." Within hours of a panel making that recommendation, the CDC director accepted...

FDA Approves Boosters for Some Teens

Specifically, those aged 16 and 17; CDC decision is pending

(Newser) - The US is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer’s vaccine, per the AP . The US and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified...

Here's How Pfizer's Vaccine Fares Against Omicron

3 doses 'offer a sufficient level of protection from disease of any severity'

(Newser) - Two doses of the Pfizer/BioNTech coronavirus vaccine may be enough to prevent serious illness with the omicron variant, but may not be enough to prevent an infection, the companies said Wednesday. However, "preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the omicron variant,"...

BioNTech Founder: Omicron Unlikely to Cause Severe Cases

Ugur Sahin says vaccinated people should have protection against new variant

(Newser) - The seesawing of sentiment on the omicron variant continues. The co-founder of BioNTech, the company that partnered with Pfizer on a COVID vaccine, has weighed in with comments that are relatively optimistic. Ugur Sahin tells the Wall Street Journal that the company's existing vaccine should prevent serious illness among...

One Potential COVID Treatment Not as Potent as Hoped

Merck's pill, awaiting FDA review, is less effective than preliminary tests suggested

(Newser) - The COVID virus keeps mutating , and drugmakers are racing to adapt along with it. But on that front, Merck reported some relatively disappointing news about a pill under development—molnupiravir turns out to be 30% effective at reducing hospitalizations and deaths, which is down from preliminary estimates of 50%, reports...

FDA Wants FOI Request on Vaccine to Wait—for 55 Years

Experts want to see information used in approving Pfizer's product

(Newser) - The experts who have filed a Freedom of Information request to see government data on the Pfizer COVID-19 vaccine might have to hand the issue down to the next generation—at least—of scientists and professors. The Food and Drug Administration has asked a judge to not force the documents'...

Stories 1 - 20 |  Next >>
Popular on Newser
We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.